Literature DB >> 16207967

Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

Dominic Hill1, Barbara Rose, Aniko Pajkos, Michael Robinson, Peter Bye, Scott Bell, Mark Elkins, Barbara Thompson, Colin Macleod, Shawn D Aaron, Colin Harbour.   

Abstract

Recent studies have determined that Pseudomonas aeruginosa can live in a biofilm mode within hypoxic mucus in the airways of patients with cystic fibrosis (CF). P. aeruginosa grown under anaerobic and biofilm conditions may better approximate in vivo growth conditions in the CF airways, and combination antibiotic susceptibility testing of anaerobically and biofilm-grown isolates may be more relevant than traditional susceptibility testing under planktonic aerobic conditions. We tested 16 multidrug-resistant isolates of P. aeruginosa derived from CF patients using multiple combination bactericidal testing to compare the efficacies of double and triple antibiotic combinations against the isolates grown under traditional aerobic planktonic conditions, in planktonic anaerobic conditions, and in biofilm mode. Both anaerobically grown and biofilm-grown bacteria were significantly less susceptible (P < 0.01) to single and combination antibiotics than corresponding aerobic planktonically grown isolates. Furthermore, the antibiotic combinations that were bactericidal under anaerobic conditions were often different from those that were bactericidal against the same organisms grown as biofilms. The most effective combinations under all conditions were colistin (tested at concentrations suitable for nebulization) either alone or in combination with tobramycin (10 microg ml(-1)), followed by meropenem combined with tobramycin or ciprofloxacin. The findings of this study illustrate that antibiotic sensitivities are dependent on culture conditions and highlight the complexities of choosing appropriate combination therapy for multidrug-resistant P. aeruginosa in the CF lung.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16207967      PMCID: PMC1248524          DOI: 10.1128/JCM.43.10.5085-5090.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms.

Authors:  H Ceri; M E Olson; C Stremick; R R Read; D Morck; A Buret
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

2.  A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.

Authors:  J Eisenberg; M Pepe; J Williams-Warren; M Vasiliev; A B Montgomery; A L Smith; B W Ramsey
Journal:  Chest       Date:  1997-04       Impact factor: 9.410

3.  Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides.

Authors:  H Kobayashi
Journal:  Am J Med       Date:  1995-12-29       Impact factor: 4.965

Review 4.  Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.

Authors:  N Høiby; C Koch
Journal:  Thorax       Date:  1990-11       Impact factor: 9.139

Review 5.  The use of macrolide antibiotics in patients with cystic fibrosis.

Authors:  Lisa Saiman
Journal:  Curr Opin Pulm Med       Date:  2004-11       Impact factor: 3.155

Review 6.  Azithromycin for cystic fibrosis.

Authors:  K W Southern; P M Barker
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

7.  Tolerance of Pseudomonas aeruginosa to killing by ciprofloxacin, gentamicin and imipenem in vitro and in vivo.

Authors:  P Davey; M Barza; M Stuart
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

8.  Inhibition of tobramycin diffusion by binding to alginate.

Authors:  W W Nichols; S M Dorrington; M P Slack; H L Walmsley
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

9.  Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa.

Authors:  C A Gordon; N A Hodges; C Marriott
Journal:  J Antimicrob Chemother       Date:  1988-11       Impact factor: 5.790

10.  Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms.

Authors:  Giorgia Borriello; Erin Werner; Frank Roe; Aana M Kim; Garth D Ehrlich; Philip S Stewart
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more
  79 in total

1.  Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa.

Authors:  Clement Mugabe; Majed Halwani; Ali O Azghani; Robert M Lafrenie; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

Review 3.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

4.  Luminescent Nanosensors for Ratiometric Monitoring of Three-Dimensional Oxygen Gradients in Laboratory and Clinical Pseudomonas aeruginosa Biofilms.

Authors:  Megan P Jewell; Anne A Galyean; J Kirk Harris; Edith T Zemanick; Kevin J Cash
Journal:  Appl Environ Microbiol       Date:  2019-10-01       Impact factor: 4.792

5.  Antibiotic resistance in an in vitro subgingival biofilm model.

Authors:  M J Sedlacek; C Walker
Journal:  Oral Microbiol Immunol       Date:  2007-10

6.  Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing Pseudomonas aeruginosa.

Authors:  Mathias Müsken; Vinay Pawar; Timo Schwebs; Heike Bähre; Sebastian Felgner; Siegfried Weiss; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 7.  Emerging Roles of Functional Bacterial Amyloids in Gene Regulation, Toxicity, and Immunomodulation.

Authors:  Nir Salinas; Tatyana L Povolotsky; Meytal Landau; Ilana Kolodkin-Gal
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

Review 8.  Options and Limitations in Clinical Investigation of Bacterial Biofilms.

Authors:  Maria Magana; Christina Sereti; Anastasios Ioannidis; Courtney A Mitchell; Anthony R Ball; Emmanouil Magiorkinis; Stylianos Chatzipanagiotou; Michael R Hamblin; Maria Hadjifrangiskou; George P Tegos
Journal:  Clin Microbiol Rev       Date:  2018-04-04       Impact factor: 26.132

9.  Evolutionary genomics of epidemic and nonepidemic strains of Pseudomonas aeruginosa.

Authors:  Jeremy R Dettman; Nicolas Rodrigue; Shawn D Aaron; Rees Kassen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

10.  Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis.

Authors:  L Dales; W Ferris; K Vandemheen; S D Aaron
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-07-03       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.